Side effect profile Both formats produce similar GLP-1-related side effects because they deliver the same active molecule
A patient who loses 15% of body weight on tirzepatide over the next 18 months will enter a retatrutide program, if they choose to transition, from a metabolically stronger position than one who waited
The Canadian CSP Register may list a CSP even if the underlying patent has lapsed, but this does not mean it is enforceable
The primary composite endpoint (cardiovascular death or worsening heart failure) was reached in 9,9% of the tirzepatide arm versus 15,3% of the placebo arm (HR 0,62, p=0,026)
However, U.S
Unlike low-touch programs, patients receive: Consistent communication with a licensed provider Flexible telehealth appointments Support for microdosing when appropriate Personalized treatment plans that evolve with progress Learn more about available programs here: GLP-1 Weight Loss Plans Why Provider-Led GLP-1 Care Matters GLP-1 medications like Semaglutide and Tirzepatide are powerful tools but results depend heavily on proper guidance